5/7
11:13 am
alrn
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround [Yahoo! Finance]
Medium
Report
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround [Yahoo! Finance]
5/6
04:10 pm
alrn
Aileron Therapeutics to Present at Two Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Aileron Therapeutics to Present at Two Upcoming Investor Conferences [Yahoo! Finance]
5/6
04:05 pm
alrn
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Medium
Report
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
5/3
04:05 pm
alrn
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Medium
Report
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
5/1
08:48 am
alrn
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million [Yahoo! Finance]
Medium
Report
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million [Yahoo! Finance]
5/1
08:45 am
alrn
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Medium
Report
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
5/1
08:39 am
alrn
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) [Yahoo! Finance]
Medium
Report
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) [Yahoo! Finance]
5/1
08:30 am
alrn
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Medium
Report
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
4/18
08:40 am
alrn
Aileron Therapeutics, Inc. (NASDAQ: ALRN) had its price target raised by analysts at LADENBURG THALM/SH SH from $9.00 to $19.00. They now have a "buy" rating on the stock.
Low
Report
Aileron Therapeutics, Inc. (NASDAQ: ALRN) had its price target raised by analysts at LADENBURG THALM/SH SH from $9.00 to $19.00. They now have a "buy" rating on the stock.
4/15
05:29 pm
alrn
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
4/15
05:20 pm
alrn
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/12
08:17 am
alrn
Aileron Therapeutics Announces CEO Transition [Yahoo! Finance]
Medium
Report
Aileron Therapeutics Announces CEO Transition [Yahoo! Finance]
3/12
08:00 am
alrn
Aileron Therapeutics Announces CEO Transition
Medium
Report
Aileron Therapeutics Announces CEO Transition
2/15
04:14 pm
alrn
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event [Yahoo! Finance]
Low
Report
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event [Yahoo! Finance]
2/15
04:05 pm
alrn
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Low
Report
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event